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p38Transforming growth factor-α-activated kinase 1 (TAK1) has been widely recognized as a kinase that
regulates multiple intracellular signaling pathways evoked by cytokines and immune receptor activation. We
have recently reported that tumor necrosis factor-α (TNF-α) triggers internalization of epidermal growth
factor receptor (EGFR) through a TAK1-p38α signaling pathway, which results in a transient suppression of
the EGFR. In the present study, we investigated the pathway of intracellular signaling in the opposite
direction. Ligand-induced activation of EGFR caused phosphorylation of the TAK1-binding proteins TAB1 and
TAB2 in a TAK1-independent manner. EGFR-mediated phosphorylation of TAB1 was completely inhibited by
a chemical inhibitor and siRNA of p38α. The phosphorylation of TAB1 was occurred at Ser-423 and Thr-431,
the residues underlying the p38-mediated feedback inhibition of TAK1. In contrast, phosphorylation of TAB2
was sustained, and largely resistant to p38 inhibition. The inducible phosphorylation of TAB1 interfered with
a response of EGF-treated cells to TNF-α-induced TAK1 activation, which led to the reduction of NF-κB
activation. Collectively, these results demonstrated that EGFR activation interfered with TNF-α-induced TAK1
activation via p38-mediated phosphorylation of TAB1.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Transforming growth factor-β-activated kinase 1 (TAK1) is one of
the most characterized mitogen-activated protein kinase kinase
kinase family (MAP3K) members and is activated by cellular stress,
including tumor necrosis factor-α (TNF-α) and interleukin-1 [1–11].
TAK1 functions as an upstream stimulatory molecule of the c-Jun N-
terminal kinase (JNK), p38, and nuclear factor-κB (NF-κB) signaling
pathways. Gene targeting has clearly demonstrated that TAK1
participates in diverse cellular functions, including the activation
and differentiation of T and B lymphocytes, and epidermal home-
ostasis involving the apoptosis of keratinocytes [12–17]. In addition,
TAK1 has been shown to be involved in several pathogenic conditions,
including inﬂammation, functional interaction with viral oncogene
products, cancer metastasis, and myocardial hypertrophy [18–22].
The protein kinase activity of TAK1 is strictly controlled by TAK1-
binding proteins (TAB) [6,11,23]. TAB1 binds to the N-terminal kinase
domain of TAK1. TAB2 and the structurally similar TAB3 function as
adaptor proteins to recruit TAK1 to TRAF2 (TNF-α receptor-associated
factor) and TRAF6 in the TNF-α and interleukin-1 signaling pathways,
respectively. We have reported that phosphorylation at Thr-187 is
essential for TAK1 activation [24,25]. It has recently been shown that81 76 434 5058.
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ll rights reserved.protein phosphatase 2A (PP2A) and PP6 are involved in the depho-
sphorylation of Thr-187 [26]. In addition, TAB1 participates in p38-
mediated negative feedback regulation of the cytokine-induced TAK1
kinase activity, in which p38 directly phosphorylates TAB1 at Ser-423
and Thr-431 [10].
Epidermal growth factor receptor (EGFR) is a member of the ErbB
receptor tyrosine kinase family and plays a critical role in a wide
variety of cellular functions, including proliferation, differentiation,
and apoptosis [27–30]. In addition to the true ligands, EGFR is trans-
activated by other extracellular stimuli, including agonists for G
protein-coupled receptors, ion channels, integrins, and cellular
stresses such as TNF-α, UV light and high osmolarity [31–37].
Recently obtained evidence has demonstrated that membrane-
bound ligands of EGFR, such as TGF-α and heparin-binding EGF, are
released and bind to the receptor in an extracellular fashion [38].
Moreover, evidence has been accumulating that TNF-α induces the
rapid and transient internalization of EGFR with no obvious activation
of its intracellular tyrosine kinase through the TAK1-p38 signaling
pathway [39,40]. In fact, TNF-α actually suppresses the extracellular
ligand-mediated activation of EGFR.
In tumor microenvironments and inﬂamed tissues, multiple
cytokines and growth factors are expressed and coordinately regulate
the pathogenic alterations. TNF-α and EGF are typical of these
secreted ligands and their pathological functions have been exten-
sively studied [41,42]. TNF-α plays a central role in inﬂammatory
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diseases [43]. In addition, attention has recently been focused on the
role of TNF-α in tumor angiogenesis and metastasis [42]. On the other
hand, overexpression, ampliﬁcation and mutations of EGFR are
involved in carcinogenesis and the progression of several types of
cancer [27–30,41]. Anti-TNF-α and anti-EGFR agents have already
been developed, and are clinically effective against these diseases,
supporting the experimental analyses of these ligands and their
receptors [43,44]. Cross talk between different signaling pathways is
likely to be important for diverse cellular functions. Therefore, we
have investigated the functional interactions of the TNF-α signal and
EGFR signal to elucidate new biological processes.
MEKK1 and Raf-1, but not TAK1, are characterized as MAP3Ks
underlying the EGFR-mediated activation of MAPKs including p38
[45,46]. As described above, p38 plays a key role in the feedback
inhibition of TAK1 through phosphorylation of TAB1 [10]. In the
present study, we have therefore investigated whether EGFR-induced,
TAK1-independent activation of p38 triggers phosphorylation of TAB
proteins and inﬂuences the TNF-α-induced activation of TAK1.
2. Materials and methods
2.1. Antibodies and reagents
An anti-phospho-TAK1 (Thr-187) antibody was described pre-
viously [25]. Other phospho-speciﬁc antibodies against p38 (Thr-180/
Tyr-182), JNK (Thr-183/Tyr-185), ERK (Thr-202/Tyr-204), p65 (Ser-
536), and EGFR (Tyr-845, Tyr-974 and Tyr-1068) and phospho-IκBα
(Ser32/36) were purchased from Cell Signaling Technology. Anti-
phospho-TAB1 (Thr-431, Ser-423, and Ser-438) antibodies were kindly
provided by Dr. Phillip Cohen (The University Dundee). Antibodies
against TAK1 (M-579), TAB1 (C-20), TAB2 (K-20), p38 (C-20-G), p65
(C-20-G), IκBα (C-21), EGFR (1005), PCNA (PC-10), Lamin B (C-20)
andα-Tubulin (B-7)were purchased from Santa Cruz Biotechnologies.
Recombinant human TNF-α and EGF were obtained from R&D
System, and SB203580, SP600125, U0126 and AG825 from Merk
Biosciences. Anisomycin was obtained from WAKO Pure Chemical
Co. Ltd. 5Z-7-oxozeaenol, a selective TAK1 inhibitor, was a gift from
Chugai Pharmaceutical Co. Ltd [47]. All the chemical inhibitors were
dissolved in DMSO and the ﬁnal concentration of DMSO was less
than 0.1 %.
2.2. Expression vectors
Expression vectors for TAK1, TAB1 and its substitution mutant
were reported previously [5,24,25]. The expression vector for TAB2
was kindly provided by Dr. Kunihiro Matsumoto (Nagoya University,
Japan). EGFR cDNA was ampliﬁed by RT-PCR and inserted into
pcDNA3.1 vector.
2.3. Cell culture and transfection
HeLa and HEK293 cells were maintained in Dulbecco's modiﬁed
Eagle's medium (high glucose) supplemented with 10% fetal calf
serum, 100 units/ml penicillin and 100 μg/ml streptomycin at 37 °C in
5% CO2. HeLa and HEK293 cells were transfected with expression
plasmids using LipofectAMINE and LipofectAMINE2000 reagents
(Invitrogen), respectively.
2.4. Preparation of cell extracts
Whole cell lysates were prepared as described previously [4].
Cytoplasmic and nuclear extracts were prepared as described
previously with some modiﬁcations [45]. In brief, cells were
suspended in 400 μl of buffer A (10 mM Hepes pH 7.9, 10 mM
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 1 mM PMSF, 20 mMβ-glycerophosphate, 0.1 mM sodium orthovanadate, 10 μg/ml
aprotinin, and 10 μg/ml leupeptin) and chilled on ice for 15 min.
Next, 25 μl of 10% Nonidet P-40 was added and the suspension
was vigorously vortexed for 10 s and kept on ice for 5 min.
Cytoplasmic extracts were collected from the supernatants of
centrifugation at 15,000 rpm for 5 min. The nuclear pellets were
washed with 100 μl of buffer A and suspended in 50 μl of buffer B
(20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA,
1 mM DTT, 1 mM PMSF, 20 mM β-glycerophosphate, 1 mM sodium
orthovanadate, 10 μg/ml aprotinin and 10 μg/ml leupeptin). The
mixture was kept on ice for 15 min with frequent agitation.
Nuclear extracts were prepared by centrifugation at 15,000 rpm for
5 min.
2.5. Immunoblotting
Cell lysates or extracts were resolved by SDS-PAGE and transferred
to an Immobilon-P nylon membrane (Millipore). The membrane was
treated with BlockAce (Dainippon Pharmaceutical Co. Ltd, Suita,
Japan) overnight at 4 °C and probed with primary antibodies as
described above. Antibodies were detected using horseradish perox-
idase-conjugated anti-rabbit, anti-mouse, anti-goat and anti-sheep
IgG (DAKO), and visualized with the ECL system (Amersham
Biosciences). Antibody reactions were carried out in the Can Get
Signal solution (TOYOBO). The speciﬁcity of antibody was conﬁrmed
by the molecular weight of the band detected using BenchMark
protein ladder (Invitrogen).
2.6. Immunoprecipitation
Cell lysates were diluted with an equal volume of dilution buffer
(20 mM HEPES, pH 7.7, 2.5 mM MgCl2, 0.1 mM EDTA, 0.05% Triton X-
100, 20 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl ﬂuoride, 1 mM dithiothreitol, 10 μg/ml aproti-
nin, and 10 μg/ml leupeptin). After centrifugation, lysates were
immunoprecipitated with anti-TAB2 antibody on ice for 1.5 h and then
rotated with protein G-Sepharose (Amersham Bioscience) at 4 °C for
1.5 h. The Sepharose beads were washed three times with wash buffer
(1:1 mixture of whole cell lysate buffer and dilution buffer).
2.7. RNA interference
Duplex siRNAs with two nucleotides overhanging at the 3′ end of
the sequencewere designed at iGENE Therapeutics and synthesized at
Hokkaido System Science Co, Ltd. The target sequences were as
follows; TAK1, UGGCUUAUCUUACACUGGA; EGFR, UGCUGGGUGCG-
GAAGUGAAAGAAUA; ErbB2, UGUCAGUAUCCAGGCUUUGUA; p38α,
GCAUUACAACCAGACAGUUGAUAUU; p38α-m, CAUUACAACCCGCCA-
GUUGAUAUU; ﬁreﬂy luciferase (GL2), CGUACGCGGAAUACUUCGA.
HeLa cells were transfected with siRNAs in a ﬁnal concentration of
30–50 nM using Lipofectamine reagents. At 72 h post-transfection,
cells were stimulated.
2.8. λ-Phosphatase reaction
TAK1 complex was immunoprecipitated with anti-TAB2 antibody
from untreated or EGF-stimulated HeLa cells, and then incubated with
λ-phosphatase (Upstate) at 37 °C for 30min. Phosphatase activity was
analyzed as mobility shift on SDS-PAGE.
2.9. Electrophoresis mobility shift assay (EMSA)
Nuclear extracts were prepared from HeLa cells and probed with a
32P-labeled oligonucleotide probe containing the consensus DNA-
binding sequence of NF-κB [5]. The protein–DNA complexes were
separated on 4% PAGE as described previously [5].
Fig. 1. TAK1 is dispensable in EGF signaling pathways. (A) HeLa cells were stimulated
with 10 ng/ml EGF and 20 ng/ml TNF-α for 5 min. Whole cell lysates were
immunoblotted with phospho-TAK1 and TAK1 antibodies. (B) Cells (2× 105 cells/6-
cm dish) were transfectedwith siRNA (40 nM) against TAK1 and luciferase (luc). At 72 h
post-transfection, the cells were stimulated with or without EGF (E) or TNF-α (T) for
5 min. Cell lysates were immunoblotted with speciﬁc antibodies.
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HEK293 cells were co-transfected with expression vectors for
TAK1, TAB1, TAB2, EGFR and a luciferase reporter plasmid under the
control of 4xκB site (Stratagene). pRL-EF1αp (kindly provided by Dr.
Tsuda) was also transfected. The luciferase activity was measured by
using the Dual-Luciferase reporter assay system (Promega).
3. Results
3.1. EGF-induced MAPK activation is independent on TAK1
TAK1 has been shown to regulate MAPK pathways from cytokine
receptors. However, the role in growth factor signaling pathways
remains to be investigated. As reported previously, treatment of
HeLa cells with TNF-α induced rapid phosphorylation of TAK1 atFig. 2. EGF-inducedmodiﬁcation of TAB1 and TAB2. (A) HeLa cells were stimulatedwith 10 ng
antibodies indicated on the left side of each panel. pYmeans the tyrosine-phosphorylated for
antibodies. (B) HeLa cells were pretreated with the indicated concentrations (μM) of PD153
lysates were immunoblotted with speciﬁc antibodies. (C) Cells were transfectedwith siRNA (
stimulated with EGF for 10 min. Cell lysates were immunoblotted with speciﬁc antibodies.Thr-187 (Fig. 1A). In contrast, no TAK1 phosphorylation was
detected in response to EGF (Fig. 1A). In addition, although
knockdown of TAK1 expression by siRNA inhibited TNF-α-induced
MAPK activation, TAK1 was dispensable in the EGF-induced
signaling pathways (Fig. 1B).
3.2. EGF-induced modiﬁcation of TAB1 and TAB2
Treatment of HeLa cells with EGF induced receptor tyrosine
activity of EGFR and activation of its downstream signaling pathways
leading toMAPKs (Fig. 2A). Here, we newly identiﬁedmodiﬁcations of
TAB1 and TAB2 as shifts in mobility on SDS-PAGE upon stimulation
with EGF (Fig. 2A). The mobility shift of TAB1 was rapidly induced
within 5 min and then returned to the control level at 30 min. On the
other hand, the mobility shift of TAB2 sustained for at least 30 min
(Fig. 2A). To investigate the pathway leading to TAB1 and TAB2 upon
EGF stimulation, we examined the effect of PD153035 and AG825,
potent and selective tyrosine kinase inhibitors for EGFR and ErbB2,
respectively. Fig. 2B shows that PD153035 inhibited the EGF-induced
mobility shift of TAB1 and TAB2 as well as phosphorylation of EGFR
and p38 (Fig. 2B). In contrast, AG825 had no inhibitory effects on these
cellular responses (Fig. 2B). Similarly, an RNAi experiment demon-
strated that EGFR, but not ErbB2, is essential for the EGF-induced
cellular responses (Fig. 2C). These results indicate that the modiﬁca-
tion of TAB1 and TAB2 was mediated by tyrosine kinase activity of
EGFR homodimer.
3.3. p38α is involved in phosphorylation of TAB1 and TAB2
To identify the kind of modiﬁcations that occurred on TAB1 and
TAB2, we ﬁrst investigated the possibility of phosphorylation. The
TAK1 complex was immunoprecipitated with anti-TAB2 antibody
from cells untreated or treated with EGF for 10 min and immunopre-
cipitates were incubated with λ-phosphatase in vitro. Fig. 3A shows
that the reduced mobility was completely restored by λ-phosphatase,
indicating that phosphorylation is involved, at least in part, in EGF-
induced modiﬁcation of TAB1 and TAB2./ml EGF for the indicated periods. Whole cell lysates were immunoblotted with speciﬁc
m of EGFR. Phosphorylation of p38, JNK, and ERKwas analyzed by their phospho-speciﬁc
035 (PD), AG825 (AG) for 30 min and then stimulated with EGF for 10 min. Whole cell
50 nM) against EGFR, ErbB2 and luciferase (luc). At 72 h post-transfection, the cells were
Fig. 4. EGF-induced phosphorylation of TAB1 at Ser-423 and Thr-431. (A) HeLa cells
were stimulated with 10 ng/ml EGF for the indicated periods. The TAK1 complex was
immunoprecipitated (IP) with anti-TAB2 antibody and then immunoblotted with
antibodies against total TAB1 and phospho-speciﬁc TAB1 antibody corresponding to
Thr-431, Ser-423 and Ser-438. (B) HeLa cells were pretreated with or without SB203580
(20 μM) for 30 min and then stimulated with EGF for 10 min. Cell lysates were
immunoprecipitated (IP) as described in A.
Fig. 3. Role of p38α in EGF-induced phosphorylation of TAB1 and TAB2. (A) HeLa cells
were stimulated with EGF for 5 min. TAB2 was immunoprecipitated (IP) from untreated
or EGF-stimulated cells and then incubated with λ-phosphatase (λ-PPase) in vitro. The
shift in mobility was analyzed by immunoblotting with antibodies against TAB1 and
TAB2. (B) HeLa cells were pretreated with 5Z-7-oxozeaenol (0.3 μM), SB203580
(20 μM), SP600125 (20 μM), or U0126 (10 μM) for 30min and then stimulated with EGF
for 10 min. Cell lysates were immunoblotted with antibodies against TAB1 and TAB2.
(C) Cells were transfectedwith siRNA (50 nM) against p38α and luciferase (luc). At 72 h
post-transfection, the cells were stimulated with EGF for 10 min. Cell lysates were
immunoblotted with antibodies against TAB1, TAB2, phospho-p38 and p38.
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stream kinases. Fig. 3B shows that phosphorylation of TAB1 was
completely inhibited by pretreatment with SB203580, an inhibitor for
p38α and p38β, while phosphorylation of TAB2 was only partially
prevented by the inhibitor. Pretreatment with SP600125 and U0126,
inhibitors for JNK and MEK1/2 (mitogen-activated protein kinase/
extracellular signal regulated kinase kinase), respectively, did not
block phosphorylation of TAB1 and TAB2 (Fig. 3B). In addition,
phosphorylation of TAB1 and TAB2 was not affected by 5Z-7-
oxozeaenol, indicating that the EGF-induced signal to TAB proteins
was not dependent on the kinase activity of TAK1 (Fig. 3B). Similar
results were obtained in experiments using siRNA against p38α. Fig.
3C shows that knockdown of p38α decreased phosphorylation of
TAB1, but only slightly inhibited phosphorylation of TAB2. These
results demonstrated that p38α is a critical mediator in EGF-induced
TAB1 phosphorylation; however, its contribution to TAB2 phosphor-
ylation is limited.
3.4. Identiﬁcation of phosphorylation sites on TAB1
To identify the phosphorylation sites of TAB1, we performed
immunoblotting with three phospho-speciﬁc anti-TAB1 antibodies
against Thr-431, Ser-423 and Ser-438, which are the sites underlying
p38-mediated feedback phosphorylation of TAB1 [10]. Unfortunately,
phosphorylation of TAB1 in cell lysates could not be detected. In
addition, anti-TAB1 antibody was unavailable for immunoprecipita-
tion (data not shown). In contrast, TAB1 was co-immunoprecipitatedwith anti-TAB2 antibody (Fig. 4). Fig. 4A shows that TAB1was strongly
phosphorylated at Ser-423 and Thr-431 from 5 min to 20 min after
stimulation with EGF. This was similar to the time course of the
mobility shift on SDS-PAGE (Fig. 2A), suggesting that the EGF-induced
mobility shift of TAB1 was mainly dependent on phosphorylation at
Thr-431 and Ser-423. The phosphorylation was completely inhibited
by SB203580, indicating a role for p38 (Fig. 4B). In contrast,
phosphorylation at Ser-438 was stably detected under the basal
conditions and was not induced by EGF. In addition, the basal
phosphorylation was resistant to treatment with SB203580 (Fig. 4B).
This is consistent with the observations that Ser-438 phosphorylation
is not suppressed by SB203580 or in p38α MAPK−/− MEFs [10], and
that JNK and ERK are possible kinases catalyzing Ser-438 phosphor-
ylation [48]. Collectively, these results demonstrated that EGF induces
phosphorylation of TAB1 at Ser-423 and Thr-431 in a p38-dependent
manner.
3.5. Transient suppression of TAK1 in EGF-treated cells
The inducible phosphorylation of TAB1 at the sites for feedback
inhibition raises the possibility that pretreatment with EGF inhibits
activation of TAK1 by TNF-α. To test this hypothesis, HeLa cells were
pretreated with EGF for the indicated periods (0–30 min), and then
stimulated with TNF-α for another 5 min in the presence of EGF.
Without the pretreatment, the 5 min TNF-α stimulation induced
phosphorylation of TAK1 at Thr-187, an indicator for the activation
status of TAK1 (Fig. 5A). Interestingly, the TNF-α-induced phosphor-
ylation of TAK1 was impaired by the pretreatment with EGF (Fig. 5A).
Notably, a signiﬁcant reduction in the activation of TAK1was observed
in cells pretreated with EGF for 5–20 min, which corresponded to the
timing of the phosphorylation of TAB1. We next investigated the
kinetics of TNF-α-induced TAK1 phosphorylation after the 10min EGF
Fig. 5. Transient suppression of TAK1 activation by EGF. (A) HeLa cells were pretreated with EGF for the indicated period and then stimulated with TNF-α for another 5 min. Whole
cell lysates were immunoblotted with anti-phospho-TAK1, anti-TAK1, anti-TAB1 and anti-TAB2 antibodies. (B) HeLa cells were treated with or without EGF for 10 min and post
treated with TNF-α for the indicated time. Whole cell lysates were immunoblotted with anti-phospho-TAK1, anti-TAK1 antibodies. (C) HeLa cells were transfected with or without
siRNA (30 nM) against wild type (wt) or mutant (mt) p38α, and luciferase (si-luc). At 72 h post-transfection, the cells were stimulated with or without EGF (for 10 min), and then
stimulated with TNF-α in the presence of EGF for another 5 min. Cell lysates were immunoblotted with antibodies against phospho-TAK1, TAK1 and p38. (D) HeLa cells were
pretreated with 20 μM and 2 μM of SB203580 for 30 min. Cells were stimulated with or without EGF for 10 min and then stimulated with TNF-α for another 5 min. Whole cell lysates
were immunoblotted with anti-phospho-TAK1, anti-TAK1 and anti-actin antibodies. (E) HeLa cells were transfected with expression vectors for wild type HA-TAB1 or its substitution
mutant (Ser-423-Ala and Thr-431-Ala, AA). At 24 h post-transfection, cells were stimulatedwith orwithout EGF for 10min, and then stimulatedwith TNF-α in the presence of EGF for
another 2.5 min. Cell lysates were immunoblotted with antibodies against phospho-TAK1, TAK1, TAB1 and TAB2. (F) HEK293 cells (1.5×106/6 cm dish) were transfected with
expression vectors for Flag-TAK1(0.5 μg), HA-TAB1 (0.5 μg) or its substitution mutant (Ser-423-Ala and Thr-431-Ala, AA) (0.5 μg), TAB2 (0.5 μg) and/or EGFR (0.5 μg). At 24 h post-
transfection, cell lysates were immunoblotted with antibodies against phospho-TAK1, TAK1, TAB1, phospho-TAB1 (Ser-423), TAB2 and EGFR. (G) HeLa cells were pretreated with
60 μMof anisomycin for 15min and then stimulatedwith TNF-α for another 5min.Whole cell lysates were immunoblotted with anti-phospho-TAK1, anti-TAK1, anti-TAB1, anti-TAB2,
anti-phospho-p38 and anti-actin antibodies.
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TAK1 phosphorylation was detected within 10 min after TNF-α
exposure. The kinetics of TAK1 phosphorylation was not affected by
the EGF pretreatment, although the intensity was signiﬁcantly
decreased (Fig. 5B).
3.6. TAK1 is negatively regulated by p38-mediated TAB1 phosphorylation
To elucidate the role of p38 in this suppression, we examined the
effects of RNA interference (RNAi). HeLa cells were transfected withwild type p38α siRNA, its mutant (p38-mt) and control luciferase
(luc) siRNA. At 72-h post-transfection, the speciﬁc knockdown of p38
expression was conﬁrmed by immunoblotting. We tried to examine
the role of p38 in the EGF-induced suppression of TAK1 in these
transfected cells. As reported previously, inactivation of p38 canceled
the feedback inhibition of TAK1, which resulted in enhanced TAK1
phosphorylation upon TNF-α stimulation (Fig. 5C, lane 4). EGF-
induced suppression of TAK1 was reproducibly detected in cells
transfected with control siRNA (Fig. 5C, lane 6). Moreover, the TNF-
α-induced TAK1 activation was clearly improved by p38α RNAi (Fig.
Fig. 6. EGF-induced suppression of TAK1 activity elicits reduced NF-κB activation. (A) HeLa cells were pretreated with EGF for 10 min and then stimulated with TNF-α for another
2 min. Whole cell lysates were immunoblotted with antibodies against phospho-p65, p65, phospho-p38 and p38. (B) HeLa cells were pretreated with EGF for 10 min and then
stimulatedwith TNF-α for another 5min. Nuclear extracts were immunoblotted with antibodies against p65 and Lamin B. Cytoplasmic extracts were immunoblotted with antibodies
against phospho-IκBα, IκBα and α-Tubulin. (C) HeLa cells were treated with or without EGF for 10 min and post treated with TNF-α for the indicated time. Nuclear extracts were
examined by immunoblotting (IB) and gel mobility shift assay (EMSA). (D) HEK293 cells (2.0×104/12-well plate) were transfected with expression vectors for Flag-TAK1 (0.5 μg),
HA-TAB1 (0.5 μg) or its substitution mutant (ST/AA) (0.5 μg), TAB2 (0.5 μg) and EGFR (0.5 μg), together with luciferase reporter plasmids driven by NF-κB and EF1α promoter.
Twenty-four hour after transfection, luciferase activities were determined. Data are the mean±S.D. of triplicates from a representative experiment.
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p38 speciﬁc inhibitor SB203580. The inhibitor at 20 μM and 2 μM
abrogated the EGF-induced suppression of TAK1 phosphorylation
(Fig. 5D, lanes 7, 8). In addition, overexpression of TAB1-ST/AA,
which has a substitution mutation in the p38-mediated phosphor-
ylation sites (Ser-423 and Thr-431), rescued the EGF-induced
suppression of TAK1 (Fig. 5E). Moreover, an overexpression experi-
ment conﬁrmed that phosphorylation of TAK1 by wild type TAB1 and
TAB2 were signiﬁcantly inhibited by co-expression of EGFR (Fig. 5F).
In contrast, TAB1-ST/AA mutant-induced phosphorylation of TAK1
was resistant to the suppression by EGFR (Fig. 5F). These results
demonstrated that EGF-induced down-regulation of TAK1 is
mediated through p38-induced phosphorylation of TAB1 at Ser-423
and Thr-431. Furthermore, anisomycin induced both p38 activation
and suppression of TNF-α-induced activation of TAK1 (Fig. 5G),
suggesting that the suppression is a common mechanism for p38-
activting agents.
3.7. EGF inhibits TNF-a-induced NF-κB activation
TNF-α and EGF have been shown to affect similar intracellular
signaling pathways including MAPKs. However, the transcription
factor NF-κB is speciﬁcally activated by TNF-α. We have reported
that TNF-α-induced phosphorylation of NF-κB p65 at Ser-536 ismediated through the TAK1 complex [49,50]. Therefore, we
investigated phosphorylation of p65 to evaluate the effect of the
EGFReceived in revised forminduced suppression of TAK1 on its
downstream signaling pathway. Cells were treated with EGF for
10 min and subsequently treated with TNF-α for another 2 min.
TNF-α-induced phosphorylation of NF-κB was reduced by the EGF
pretreatment (Fig. 6A). Similarly, the EGF pretreatment inhibited
nuclear translocation of p65, phosphorylation and degradation of
IκBα (Fig. 6B). We next investigated the kinetics of TNF-α-induced
NF-κB activation after the 10 min EGF pretreatment. Western blot
analysis and EMSA demonstrated that NF-κB activation in EGF-
treated cells was reduced at all the time points tested (Fig. 6C). In
addition, TAK1 complex (TAK1, TAB1 and TAB2)-induced NF-κB-
dependent reporter gene expression was suppressed by EGFR in
HEK293 (Fig. 6D). Similar to the effect on TAK1 (Fig. 5D), the
substitution TAB1 mutant was resistant to the suppression by EGFR.
These results indicate that the reduced activation of TAK1 was
correlated with the selective suppression of TNF-α-induced activa-
tion of NF-κB.
4. Discussion
EGFR is activated by natural ligands as well as other extracellular
stimuli. It has recently been demonstrated that EGFR plays a role in the
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mary epithelial cells. Geﬁtinib, a selective EGFR tyrosine kinase
inhibitor, blocks TNF-α-induced metastatic properties in mouse
hepatocellular carcinoma cells [35–37]. Moreover, we have recently
reported that TNF-α suppresses extracellular EGF responses through
internalization of the EGFR [40], a process in which the TAK1-p38α
signaling pathway regulates phosphorylation of EGFR at unidentiﬁed
sites other than the known major intracellular tyrosine residues (Figs.
1 and 7). In the present study, we demonstrated the pathway of
suppressive signaling in the opposite direction. EGFR-mediated
activation of p38α induced phosphorylation of TAB1 at the feedback
sites in a TAK1-independent manner, which resulted in an attenuation
of TNF-α-induced TAK1 activation. Fig. 1B showed that TAK1 was
dispensable in the EGF-induced p38 activation. Among the other
MAP3Ks, MEKK1, 2, 3, and 4 have been shown to mediate MAPK
activation by EGF [41,42]. Collectively, these results indicate that the
TNF-α and EGFR signaling pathways interfere with each other, where
p38α is a common mediator connecting both directions of suppres-
sive signals.
TAK1 catalytic activity is controlled by the TAK1-binding proteins
TAB1, TAB2 and TAB3. In an overexpression experiment, TAB1 was
the most potent activating protein among TAK1-binding proteins.
The role of TAB1 in TAK1 activation was conﬁrmed in TAB1−/−
mouse embryonic ﬁbroblastic cells (MEFs), in which cytokine-
induced phosphorylation of TAK1 at Thr-187 was reduced as
compared with that observed in wild type MEFs [48,51]. In addition
to this activating potential, it is interesting that TAB1 is also
involved in the negative feedback regulation of TAK1 activity
[10,48]. The cytokine-induced activation of p38 via TAK1 resulted
in the inducible phosphorylation of TAB1 at Ser-423 and Thr-431. In
the present study, we found that the EGFR-mediated signal mimics
the p38α-TAB1 inhibitory pathway to prevent cytokine-induced
TAK1 activation. However, a critical difference between the feedback
inhibition and EGF-induced inhibition is whether the p38-TAB1-
mediated inhibitory signal is dependent on TAK1 kinase activity or
not. Therefore, this is the ﬁrst report demonstrating a preventiveFig. 7. A schematic diagram for cross interference between TNF-α and EGF signaling pathwa
shownwith a solid arrow. EGFR is phosphorylated at unidentiﬁed residues through p38α, wh
dashed arrow. The EGFR-mediated signal prevents TNF-α-induced phosphorylation of TAK1mechanism for cytokine-induced TAK1 activation. It has recently
been reported that other phosphorylation sites in the activation
loop of TAK1 (Thr-178 and Thr184) play regulatory role in TAK1
activation [52]. Study focused on these sites will provide more
information for the suppression and negative feedback inhibition of
TAK1 by the p38-TAB1 pathway.
p38α MAPK is activated mainly by the upstream MAPK kinases
(MAP2Ks), MKK3 and MKK6. As compared to the limited number of
MAP2Ks, many MAP3Ks have been shown to relay p38 signaling in
response to a wide variety of cellular stimuli. Although TAK1 plays a
central role in signaling from pro-inﬂammatory cytokine receptors
and immunoreceptors, it is unlikely to participate in a large number
of p38-activating stimuli. Therefore, a preventive mechanism for
TAK1 activation via p38-TAB1 may generally occur in response to
cellular p38-activating stimuli including EGF. It is further interesting
that TAB1 has been shown to directly activate p38 in a MKK- and
TAK1-independent manner [53]. TAB1β, a splicing variant of TAB1
which lacks the TAK1-binding region but has the p38-binding
region, has been shown to be involved in the invasiveness of breast
cancer cells [54]. These observations suggest that p38-mediated
phosphorylation of TAB1 affects TAK1-independent functions of
TAB1. Therefore, the p38-TAB1 interaction may play a key role in
TAK1-dependent and -independent cellular events.
TAB2 and TAB3 are structurally related and suggested to have a
redundant function [6,11]. These proteins are also phosphorylated
in response to TNF-α and IL-1. Mendoza et al. recently identiﬁed
the cytokine-induced phosphorylation sites in TAB2 (Ser-372, Ser-
524 and Ser-582) and TAB3 (Ser-60, Thr-404 and Ser-506) [48].
Ser-372 and Ser-524 in TAB2 structurally correspond to Thr-404
and Ser-506 in TAB3. However, it is quite interesting that although
all the sites in TAB3 and Ser-582 in TAB2 are phosphorylated
through p38α, the other sites in TAB2 are independent of p38α.
This is correlated with our ﬁnding that EGF-induced phosphoryla-
tion of TAB2 was largely resistant to inactivation of p38α. In spite
of the identiﬁcation of phosphorylation sites, the functional
importance of TAB2 and TAB3 in the feedback TAK1 inhibition isys. The TNF-α-induced signaling pathway from TNF receptor type I (TNF-RI) to EGFR is
ich leads to endocytosis. The EGF-induced signaling pathway from EGFR is shownwith a
through p38α-mediated phosphorylation of TAB1.
1163M.-S. Shin et al. / Biochimica et Biophysica Acta 1793 (2009) 1156–1164still unknown. The kinetics of the cytokine-induced phosphoryla-
tion of TAB2 and TAB3 was similar to that of TAB1. This is the case
in the EGF-induced phosphorylation of TAB2. Although we have
not yet addressed the phosphorylation of TAB3 in EGF-treated cells,
these results suggest a possible involvement of TAB2 and TAB3 in
cytokine-induced negative feedback control and the EGF-induced
prevention of TAK1 activation.
The physiological function of the cross interference between the
TNF-α and EGF signaling pathways is not yet understood. It is
important that these suppressive signals are transient. In the case of
TNF-α-induced EGFR suppression, p38-mediated internalization is
triggeredwithin 10min, and then EGFR is dephosphorylated to recycle
back to the cell surface at 60 min. The recycled EGFR is able to respond
again to extracellular ligands. In the present study, we showed that
p38-TAB1-mediated suppression of TAK1 was detected mainly at 5–
20 min after the EGF stimulation. These results raise the possibility
that, in tissue microenvironments presenting multiple kinds of
extracellular ligands, intracellular signals triggered by one receptor
interfere with signals from another receptor to predominantly
incorporate the earlier signals. In any case, more investigation is
needed to understand the physiological and pathological signiﬁcance
of the transient cross interference of intracellular signals.
In summary, we have found a novel intracellular communication
network between the TNF-α and EGF signaling pathways. These
ﬁndings raise the possibility that cellular responses to more than one
ligand differ in their order of stimulation. Therefore, systematic
analyses of short-term lag stimulation will provide new insight into
the biological responses of the cell.
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